Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalFRA:ZCY -2.08%63 PS Ratio is 0.85 as of Jul. 19, 2026, which is 55% below its 10-year median of 1.89. GuruFocus rates FRA:ZCY with a GF Score™ of 63/100 and a GF Value™ of €4.46 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 661 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 66.72% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cryo-Cell International's share price is €2.82.
Cryo-Cell International's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was €3.31. Hence, Cryo-Cell International's PS Ratio for today is 0.85.
The historical rank and industry rank for Cryo-Cell International's PS Ratio or its related term are showing as below:
FRA:ZCY'
s PS Ratio Range Over the Past 10 Years
Min: 0.75 Med: 1.89 Max: 3.91
Current: 0.9
During the past 13 years, Cryo-Cell International's highest PS Ratio was 3.91. The lowest was 0.75. And the median was 1.89.
FRA:ZCY's PS Ratio is ranked better than 66.72% of 661
companies
in the Healthcare Providers & Services industry
Industry Median: 1.52
vs FRA:ZCY: 0.90
Cryo-Cell International Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Cryo-Cell International was -1.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 1.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.00% per year.
During the past 13 years, Cryo-Cell International's highest 3-Year average Revenue per Share Growth Rate was 97.80% per year. The lowest was -18.00% per year. And the median was 8.20% per year.
Back to Basics: PS Ratio
Cryo-Cell International (FRA:ZCY) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Cryo-Cell International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cryo-Cell International's Share Price of today is €2.82. Cryo-Cell International's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.31.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cryo-Cell International (FRA:ZCY) has a PS Ratio of 0.85 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cryo-Cell International and its competitors. This is 55% below median its historical median of 1.89. Over the past decade, Cryo-Cell International's PS Ratio has ranged from 0.75 to 3.91. According to the industry distribution chart, Cryo-Cell International ranks #220 out of 661 companies in the Healthcare Providers & Services industry, placing it in the top 33.3%.
Is Cryo-Cell International's PS Ratio too high?
Cryo-Cell International's current PS Ratio of 0.85 is 55% below median its 10-year median of 1.89. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 3.91. The Healthcare Providers & Services industry median PS Ratio is 1.52. Cryo-Cell International's value of 0.85 is 44.1% below this industry median. Based on the distribution chart, Cryo-Cell International ranks #220 out of 661 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's PS Ratio compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #220 out of 661 companies for PS Ratio. This puts Cryo-Cell International in the upper half of its industry. The industry median PS Ratio is 1.52. Cryo-Cell International's value of 0.85 is 44.1% below this benchmark. Historically, Cryo-Cell International's own PS Ratio has ranged from 0.75 to 3.91 over the past decade. While the company's 10-year median is 1.89 vs. the industry median of 1.52, Cryo-Cell International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.52, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current PS Ratio of 0.85 is 44.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current PS Ratio is 0.85, which is 55% below median its own 10-year median of 1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (FRA:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.46, compared to a current price of €2.82 — trading 36.8% below its estimated fair value. The current PS Ratio is 0.85, which is 55% below median its 10-year median of 1.89 and 44.1% below the Healthcare Providers & Services industry median of 1.52. Cryo-Cell International's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current PS Ratio is 0.85 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.82 is trading 36.8% below its estimated GF Value™ of €4.46.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for FRA:ZCY:
PS Ratio: 0.85 (55% below median its 10-year median of 1.89)
GF Value™: €4.46 vs. price of €2.82 (36.8% below fair value)
Industry Position: 44.1% below the Healthcare Providers & Services median (#220 of 661)
No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
63GF Score
Get the complete analysis for FRA:ZCY
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZCY has been successfully added to your 
